Health Condition 1: H309- Unspecified chorioretinal inflammation
Conditions
Interventions
Intervention1: Brolucizumab: single dose of 0.05 mL containing 6 mg. Pro Re Nata frequency each 4 weeks
Control Intervention1: NIL: NIL
Sponsors
Anuj Sanjay Pawar
Chitra Sunov
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed CNV patients of any cause with involvement of central macula or within 500 microns of the macula.
Exclusion criteria
Exclusion criteria: Already treated cases Visually significant cataract Pregnancy History of CVA, myocardial infarction within three months CKD Stage 4 onwards patients, diabetic nephropathy One eyed patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of macular fluid, as determined by OCT, Improvement in Best corrected Visual AcuityTimepoint: Resolution of macular fluid, as determined by OCT, Improvement in Best corrected Visual Acuity at 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks 72 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| MEASUREMENT IN mean best-corrected visual acuity (BCVA) change from baseline to Week 72 (margin: 4 letters). Other key end points included the percentage of patients who maintained q12w dosing through Week 72 and anatomic outcomes.Timepoint: WEEK 48, WEEK 72 | — |
Countries
India
Contacts
Public ContactAnuj Sanjay Pawar
Jawaharlal nehru hospital and reserach centre sector 9 bhilai
Outcome results
None listed